Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration
Chiara Lonati(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Marco Moschini(Vita-Salute San Raffaele University), Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Soria(Medical University of Vienna), Wojciech Krajewski(Wroclaw Medical University), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), Anne Sophie Valiquette(Fundación Instituto Valenciano de Oncología), Tobias Klatte(Helios Hospital Bad Saarow), Giancarlo Marra(Royal Free London NHS Foundation Trust), David D‘Andrea(Medical University of Vienna), Paolo Gontero(Fondazione Ricerca Molinette), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Renzo Colombo(University of Insubria), Roberto Carando(Luzerner Kantonsspital), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Maria Angela Cerruto(University of Verona), Philipp Baumeister(University of Lucerne), Soichiro Yoshida(Tokyo Medical and Dental University), Francesco Montorsi(Vita-Salute San Raffaele University), Morgan Rouprêt(Sorbonne Université), Jeremy Yuen‐Chun Teoh(Chinese University of Hong Kong), Agostino Mattei(Luzerner Kantonsspital), Alessandro Antonelli(University of Verona), S Ausim Azizi(The Netherlands Cancer Institute), Ekaterina Laukhtina(Sechenov University), Kees Hendricksen(The Netherlands Cancer Institute), Shahrokh F. Shariat(Universitätszahnklinik Wien), Rodolfo Hurle(IRCCS Humanitas Research Hospital), Claudio Simeone(University of Brescia), Andrea Necchi(Vita-Salute San Raffaele University), A. Masson-Lecomte(Université Paris Cité), Yasuhisa Fujii(Tokyo Medical and Dental University), Stefania Zamboni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Gerald Bastian Schulz(University of British Columbia), Livio Mordasini(University Hospital of Bern), Alessandro Tafuri(University of Verona)
Cited by 20
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688